Long-Term Pharmacotherapy of Obesity
Table of Contents
Select a slide or start at the
beginning
.
(Untitled)
WEIGHT
(Untitled)
(Untitled)
(Untitled)
OBESITY MORBIDITY
(Untitled)
(Untitled)
BODY ENERGY USES
(Untitled)
(Untitled)
WAIST-TO-HIP RATIO
(Untitled)
(Untitled)
(Untitled)
SEROTONIN
SEROTONIN
(Untitled)
(Untitled)
(Untitled)
(Untitled)
(Untitled)
(Untitled)
WEIGHT LOSS TREATMENT RESULTS
WEIGHT LOSS TREATMENT RESULTS
(Untitled)
ANTIOBESITY AGENTS
PHARMACOTHERAPY
(Untitled)
(Untitled)
(Untitled)
(Untitled)
(Untitled)
(Untitled)
(Untitled)
(Untitled)
(Untitled)
PROSPECTS FOR THE FUTURE
(Untitled)
(Untitled)
LEPTIN
SIBUTRAMINE
ORLISTAT,HYDROLIPSTATIN
BROMOCRIPTINE
NEUROPEPTIDE Y1 ANTAGONIST
NEUROPEPTIDE Y5 ANTAGONIST
GALANIN RECEPTOR ANTAGONISTS
PANCREATIC LIPASE INHIBITORS
HORMONES
BETA3 ADRENERGIC RECEPTOR AGONISTS
CHOLECYSTOKININ-8 AGONISTS
(Untitled)
(Untitled)
LONG TERM PHARMACOTHERAPY IN OBESITY